Contributions
Abstract: PB1888
Type: Publication Only
Background
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease however, the incidence is increasing and closely associated with helicobacter pylori (HP) infection. One choice of treatment of gastric MALT lymphoma refractory to HP sterilization is radiotherapy.
Aims
Our aim was to analyze the response to treatment with definitive radiotherapy in our department.
Methods
Between January 2014 and January 2017, 8 patients with gastric MALT lymphoma were treated with eradication therapy of HP, followed by definitive radiotherapy. The average total dose was of 38 Gy to the stomach in a once-daily scheme. Follow-up included computed tomography scan and endoscopy with biopsies at regular intervals. The median follow-up was 14 months.
Results
In all patients we got complete responses (CR) with no tumor detectable by endoscopy or biopsy after initial treatment, but after 2 years one of them relapsed and required immunochemotherapy. The most common acute toxicities were fatigue and nausea, in our patients. In any case late toxicities were observed. The overall survival was 100% after 2 years.
Conclusion
In selected patients who are not responsive to HP sterilization, definitive radiotherapy can be an efficient therapy with tolerable complications, preservation of stomach and sustained response over time.
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Radiotherapy, MALT lymphoma, Gastric MALT lymphoma
Abstract: PB1888
Type: Publication Only
Background
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease however, the incidence is increasing and closely associated with helicobacter pylori (HP) infection. One choice of treatment of gastric MALT lymphoma refractory to HP sterilization is radiotherapy.
Aims
Our aim was to analyze the response to treatment with definitive radiotherapy in our department.
Methods
Between January 2014 and January 2017, 8 patients with gastric MALT lymphoma were treated with eradication therapy of HP, followed by definitive radiotherapy. The average total dose was of 38 Gy to the stomach in a once-daily scheme. Follow-up included computed tomography scan and endoscopy with biopsies at regular intervals. The median follow-up was 14 months.
Results
In all patients we got complete responses (CR) with no tumor detectable by endoscopy or biopsy after initial treatment, but after 2 years one of them relapsed and required immunochemotherapy. The most common acute toxicities were fatigue and nausea, in our patients. In any case late toxicities were observed. The overall survival was 100% after 2 years.
Conclusion
In selected patients who are not responsive to HP sterilization, definitive radiotherapy can be an efficient therapy with tolerable complications, preservation of stomach and sustained response over time.
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Radiotherapy, MALT lymphoma, Gastric MALT lymphoma